Cerebrolysin in Alzheimer’s disease: pooled randomized trials
Gauthier S · 2015 · Dementia and Geriatric Cognitive Disorders
Reported findings and study design
Pooled estimates of cognition and global clinical change from randomized placebo-controlled trials.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cognition at four weeks | Standardized mean difference −0.40 (95% CI −0.66 to −0.13). | |
| Cognition at six months | Standardized mean difference −0.37 (95% CI −0.90 to 0.16). | |
| Global clinical change at six months | Odds ratio 4.98 (95% CI 1.37 to 18.13). |
The pooled data include previously reported trials. The six-month cognitive estimate was inconclusive.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The pooled data include previously reported trials. The six-month cognitive estimate was inconclusive.
Source access
Original abstract checked for selected methods and findings.
Source reviewed 2026-11-12.
Source type: Journal publication
DOI: 10.1159/000377672
Citation and original source
Original source: Gauthier S. Cerebrolysin in Alzheimer’s disease: pooled randomized trials Dementia and Geriatric Cognitive Disorders 2015.
Molekul research summary: https://molekul.io/research/cerebrolysin-alzheimers-meta-2015. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry